Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

Background fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (ms). In the phase 3, 2-year freedoms (fty720 research evaluating effects of daily oral therapy in ms) study, fingolimod significantly reduced annualised relapse rates (arrs) and the risk of confirmed disability progression compared with placebo. We aimed to investigate whether the beneficial treatment effect reported for the overall population is consistent in subgroups of patients with different baseline characteristics.